- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, Maintenance Vitamin D, No maintenance Vitamin D
- Drug
- Lead sponsor
- Amany Keruakous, MD, MS.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–703
of 703
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide
- Drug
- Lead sponsor
- Eden Biltibo
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Chronic Lymphocytic Leukemia, CLL, Untreated, Front-line, First-Line, Initial Therapy
- Interventions
- Lenalidomide and Rituximab
- Drug
- Lead sponsor
- Chronic Lymphocytic Leukemia Research Consortium
- Network
- Eligibility
- Not listed
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 5
- States / cities
- La Jolla, California • Boston, Massachusetts • New Hyde Park, New York + 2 more
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma
- Interventions
- Ulocuplumab, Lenalidomide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- lenalidomide
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Pomalidomide-containing regimens, Non-pomalidomide-containing regimens
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Revlimid (Lenalidomide)
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York